Within this review, we summarize and discuss the biological background of immune-checkpoints (with focus on PD-1), specific promising combination partners for immune-checkpoint blockade (kinase inhibitors, tumor-specific vaccinations, CAR-T cells) and response prediction to ICI by artificial intelligence (with focus on the antigen presenting pathway) including the applicability of radiomics. This evidence concerns the gene PDCD1 and neoplasm.